Pancreatic Adenocarcinoma Gene Environment Risk Study (PAGER)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00912717 |
Recruitment Status
:
Recruiting
First Posted
: June 3, 2009
Last Update Posted
: July 24, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Pancreatic Cancer |
Study Type : | Observational |
Estimated Enrollment : | 10000 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | The Pancreatic Adenocarcinoma Gene Environment Risk Study -A Prospective Cohort Study of Patients at Risk or Having Pancreatic Disease |
Study Start Date : | January 2004 |
Estimated Primary Completion Date : | December 2020 |
Estimated Study Completion Date : | December 2020 |
Group/Cohort |
---|
Pancreatic Cancer
individuals who have been diagnosed with pancreatic cancer
|
Unaffected
individuals who have not been diagnosed with pancreatic cancer
|
- The data will be used in cohort association studies. Endpoints will depend on the number of patients in the study and the number of markers that are being evaluated. [ Time Frame: 10 years ]
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Histologically confirmed or CT confirmed diagnosis of pancreatic adenocarcinoma
- Subjects with abnormal imaging study (CT, MRI, MRCP, EUS)
- Control subjects with a clinical diagnosis of a pancreas, liver, or intestinal condition
- Control subject with acute pancreatitis
- Control subject with chronic pancreatitis
- Control subject with biliary obstruction
- Control subject with pancreatic cyst
- Member of a high risk family (≥ 1 close relative with pancreatic cancer)
- Healthy control (without any of the above conditions)
Exclusion Criteria:
- Under the age of 18 years
- Unable to give informed consent
- Inability to travel to Pittsburgh for in-person enrollment

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00912717
Contact: Randall E Brand, MD | 412-623-3105 | brandre@upmc.edu | |
Contact: Beth Dudley, MS, MPH, CGC | 412-623-3105 | dudleyre@upmc.edu |
United States, Pennsylvania | |
University of Pittsburgh | Recruiting |
Pittsburgh, Pennsylvania, United States, 15213 | |
Contact: Randall E Brand, MD 412-623-3105 brandre@upmc.edu |
Principal Investigator: | Randall E Brand, MD | University of Pittsburgh |
Responsible Party: | Randall Brand, M.D., University of Pittsburgh |
ClinicalTrials.gov Identifier: | NCT00912717 History of Changes |
Other Study ID Numbers: |
PRO07030072 |
First Posted: | June 3, 2009 Key Record Dates |
Last Update Posted: | July 24, 2017 |
Last Verified: | July 2017 |
Additional relevant MeSH terms:
Pancreatic Diseases Adenocarcinoma Pancreatic Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Digestive System Neoplasms Neoplasms by Site Endocrine Gland Neoplasms Digestive System Diseases Endocrine System Diseases |